Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.
about
Clinical indications for thrombopoietin and thrombopoietin-receptor agonistsAdvances in Diagnosis and Treatments for Immune ThrombocytopeniaLong-term safety and efficacy of romiplostim for treatment of immune thrombocytopeniaCurrent Management of Primary Immune ThrombocytopeniaImmune thrombocytopeniaContemporary management of primary immune thrombocytopenia in adultsHelicobacter pylori Eradication in Patients with Immune Thrombocytopenic Purpura: A Review and the Role of BiogeographyInternational comparisons of intensive care: informing outcomes and improving standardsChildhood immune thrombocytopenia: Clinical presentation and managementA systematic evaluation of laboratory testing for drug-induced immune thrombocytopeniaLaparoscopic splenectomy for primary immune thrombocytopenia: Current status and challengesThe Centenary of Immune Thrombocytopenia - Part 1: Revising Nomenclature and PathogenesisSafety and efficacy of Gammaplex® in idiopathic thrombocytopenic purpura (ClinicalTrials.gov--NCT00504075)Differential Expression Analysis by RNA-Seq Reveals Perturbations in the Platelet mRNA Transcriptome Triggered by Pathogen Reduction SystemsThe European Hematology Association Roadmap for European Hematology Research: a consensus documentFrequently asked questions on seven rare adverse events following immunization.Thrombocytopenia and infections.Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis.Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.Childhood Immune Thrombocytopenia: Long-term Follow-up Data Evaluated by the Criteria of the International Working Group on Immune Thrombocytopenic PurpuraThrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.Mycophenolate mofetil for the treatment of children with immune thrombocytopenia and Evans syndrome. A retrospective data review from the Italian association of paediatric haematology/oncology.Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.The ITP syndrome: pathogenic and clinical diversity.Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy.Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases.Raised expression of APRIL in Chinese patients with immune thrombocytopenia and its clinical implications.A retrospective analysis of therapeutic responses to two distinct corticosteroids in 259 children with acute primary idiopathic thrombocytopenic purpura.Efficacy and safety of anti-D for treatment of adults with immune thrombocytopenia.Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpuraSingle nucleotide polymorphism in the methyl-CpG binding domain 4 gene and the risk for immune thrombocytopenic purpura in Chinese population.The expression of IFN-gamma, IL-4, Foxp3 and perforin genes are not correlated with DNA methylation status in patients with immune thrombocytopenic purpura.Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research DatabaseGenetic studies in pediatric ITP: outlook, feasibility, and requirements.Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principleEltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations.Predictors for splenectomy among patients with primary chronic immune thrombocytopenia: a population-based cohort study from Denmark.The clinical outcome of 260 pediatric ITP patients in one center.Efficacy and safety of a new intravenous immunoglobulin 10% formulation (octagam® 10%) in patients with immune thrombocytopenia.Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis.
P2860
Q24601161-B34E9C87-2D45-4B80-BB86-C965356DA8F0Q26738630-457B3009-B90D-4E54-87E9-2B8915B1C522Q26745753-A7A4035D-A5E4-4AD8-90CD-C39687C11AEFQ26779408-A445B7E8-E05F-4C27-A90B-1EAB89C67175Q26830918-2ECD2F3B-A940-4B35-8CAC-E4C2FF79E512Q26853680-01679DB6-3FC8-4FCE-893C-002B65F13DBCQ26865062-ED5B57BE-B192-4729-A66C-6493453ED72AQ27008951-BF92CEF4-8EAB-498B-99D0-A07F8AD280E0Q27023294-97152C84-8873-4144-9AF7-C28BE96D4754Q27686838-D1060D63-D84F-4BBF-977E-26DC8356CC9AQ28066579-9DAB5D5F-40F6-4060-815D-76F976C92A0CQ28068881-CD30C0BB-1A2D-4A78-BAC7-C69F183581BCQ28539282-E2BD2C16-9C33-4506-937E-332AEDCCABB1Q28546504-395CEEBB-F3A6-40F2-B0B2-EC33E07FE881Q28830861-8A2E5664-E863-4452-968E-FD4C45EEF301Q30234430-323CC295-9F51-4DC5-9BCD-D9D960941886Q30240119-CD74C917-F036-4FAC-A3FA-D2A5069C42F2Q30250259-ACF76D31-281A-4589-9671-B1D13EF570BFQ30399669-4D2CEF8F-834B-488A-ABB8-FBCEC151744EQ30808680-D4559E9D-09C2-4654-8153-8A1C6B04469BQ31089024-7CC494DC-6A07-4DD0-B080-94D94A3CB9F9Q31116844-165F3396-1CF4-4CC6-8298-66CB3342513BQ31158985-AFA3B530-18A6-4243-9928-5D7044830A5EQ33384235-E4FC9AF0-C8FB-4B2F-AFE8-5D99ABBD9192Q33386133-1F7C5AF1-717F-4A2F-BF58-2C5005F6EE11Q33386303-62D526B6-1AE3-4AB4-ADE6-7328A03CE0C0Q33386608-24ECEF2F-ABAC-4BB2-B0B9-422DE8E0B8B4Q33386717-BB0D03E9-5469-4556-B660-B5FF947ADEAEQ33386764-E574DA17-3935-4110-A392-54ADC5D3B4D1Q33387105-69183499-94F9-4B16-86BB-4E1E61B3F3A7Q33387960-3BCF5340-F0DF-4240-BA93-ADC759D606A3Q33387962-1A0B7940-2B7D-4146-92D3-360BD48FDD2AQ33388213-D1178179-2A02-4487-A257-AAD07A45234BQ33388868-D6F35652-E97D-43A0-AECC-613D8239C5C7Q33390001-F2DCA1EC-CFCD-4F01-BE10-2171BCE6D729Q33391229-D2E7378A-442C-4714-9CAC-E17E5899E5A7Q33391381-29711C96-7EEE-4486-BC31-332577D65BDBQ33391421-BCE5D69C-9369-4E7C-9BF0-8D42914C194AQ33391987-80AA8760-E7C2-43B3-9E48-AA5191364A5DQ33392179-24B122D0-5CB2-4C9C-A4AB-5A6F2F0D771E
P2860
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Standardization of terminology ...... n international working group.
@ast
Standardization of terminology ...... n international working group.
@en
type
label
Standardization of terminology ...... n international working group.
@ast
Standardization of terminology ...... n international working group.
@en
prefLabel
Standardization of terminology ...... n international working group.
@ast
Standardization of terminology ...... n international working group.
@en
P2093
P50
P1433
P1476
Standardization of terminology ...... n international working group.
@en
P2093
Beng H Chong
Donald M Arnold
Douglas B Cines
Drew Provan
Francesco Rodeghiero
James N George
Klaus Lechner
Marc Michel
Marco Ruggeri
Maria Gabriella Mazzucconi
P304
P356
10.1182/BLOOD-2008-07-162503
P407
P577
2008-11-12T00:00:00Z